ONO Pharmaceutical Co (4528) AI Stock Analysis

• Market Cap: ¥782.90B
• Dividend Yield: 4.16%
• Average Volume (3M): 2.57M
• Price to Earnings (P/E): 10.6
• Beta (1Y): 0.43
• Revenue Growth: -2.16%
• EPS Growth: -40.39%
• Country: JP
• Employees: 3,853
• Sector: Healthcare
• Sector Strength: 60
• Industry: Drug Manufacturers - General
• EPS (TTM): 31.83
• Shares Outstanding: 498,692,800
• 10 Day Avg. Volume: 1,930,350
• 30 Day Avg. Volume: 2,566,710
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,399.77
• Price Target Upside: -16.03% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

ONO Pharmaceutical Co is supported by strong financial performance, underscored by robust profitability and financial management. The valuation is attractive with a reasonable P/E ratio and a good dividend yield. Technical analysis indicates a neutral trend, with potential upward momentum suggested by the MACD. The lack of recent earnings call data limits insight into future guidance.

ONO Pharmaceutical Co Business Overview & Revenue Model

Company Description

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

How the Company Makes Money

ONO Pharmaceutical Co. generates revenue primarily through the sale of its pharmaceutical products. The company's revenue streams are largely driven by the commercialization of its proprietary drugs, which include treatments in areas like oncology and immunology. A significant portion of its income comes from the sales of Opdivo, an immune checkpoint inhibitor used in cancer treatment. Additionally, ONO Pharmaceutical benefits from strategic partnerships and collaborations with other pharmaceutical companies, which help in co-developing and marketing new drugs. These partnerships often involve licensing agreements and milestones that contribute to its financial performance. The company also invests in research and development to sustain its pipeline of innovative drugs, thereby ensuring future revenue growth.

ONO Pharmaceutical Co Financial Statement Overview

Summary

ONO Pharmaceutical Co showcases strong financial health with robust profitability, effective financial management, and consistent revenue growth. The company's low leverage and strong equity base further reinforce its stability and growth potential.

Income Statement

ONO Pharmaceutical Co has demonstrated strong financial performance with a solid Gross Profit Margin of 72.43% and a commendable Net Profit Margin of 15.19% over the TTM (Trailing-Twelve-Months). The company has shown a consistent revenue growth trajectory, with a notable revenue increase of 8.97% from 2023 to 2024. The EBIT Margin of 18.26% and EBITDA Margin of 22.43% further highlight the company's operational efficiency and robust profitability.

Balance Sheet

The balance sheet of ONO Pharmaceutical Co reflects strong financial health with a low Debt-to-Equity Ratio of 0.19, indicating prudent financial leverage. The Return on Equity (ROE) of 9.07% demonstrates effective use of shareholder equity. Additionally, the Equity Ratio stands at 75.40%, showcasing a solid equity base and financial stability.

Cash Flow

ONO Pharmaceutical Co's cash flow analysis reveals a stable financial standing, with a Free Cash Flow to Net Income Ratio of 1.06 and an Operating Cash Flow to Net Income Ratio of 1.25 in the TTM (Trailing-Twelve-Months). While Free Cash Flow experienced a decline of 13.09% compared to the previous year, the company maintains positive cash generation capabilities.

Breakdown
Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
502.67B	447.19B	361.36B	309.28B	292.42B
	Gross Profit
375.55B	337.13B	267.85B	223.71B	213.36B
	EBIT
163.10B	141.96B	103.19B	98.33B	77.49B
	EBITDA
181.98B	167.50B	128.54B	114.54B	94.00B
	Net Income Common Stockholders
127.98B	112.72B	80.52B	75.42B	59.70B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
166.14B	164.29B	116.97B	104.97B	100.42B
	Total Assets
913.67B	882.44B	739.20B	746.84B	673.44B
	Total Debt
8.86B	9.17B	8.80B	9.05B	8.36B
	Net Debt
-157.28B	-86.97B	-60.31B	-51.99B	-60.64B
	Total Liabilities
115.06B	134.62B	77.53B	105.69B	105.42B
	Stockholders Equity
792.96B	741.87B	655.91B	635.55B	562.48B
Cash Flow		Free Cash Flow
89.83B	145.11B	49.55B	53.68B	51.71B
	Operating Cash Flow
110.66B	159.61B	61.83B	73.98B	74.16B
	Investing Cash Flow
48.08B	-100.26B	6.04B	-57.59B	-10.23B
	Financing Cash Flow
-89.85B	-32.48B	-60.24B	-24.75B	-54.72B

ONO Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1667.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4528, the sentiment is Positive. The current price of 1667 is below the 20-day moving average (MA) of 1676.05, above the 50-day MA of 1631.88, and below the 200-day MA of 1779.55, indicating a neutral trend. The MACD of 6.84 indicates Positive momentum. The RSI at 51.52 is Neutral, neither overbought nor oversold. The STOCH value of 24.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4528.

ONO Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4507	87 Outperform	$2.16T	12.41	13.11%	2.67%	1.58%	12.48%
4519	79 Outperform	¥14.17T	34.58	22.80%	1.02%	17.96%	25.65%
4503	77 Outperform	¥2.63T	51.43	3.22%	4.87%	19.25%	294.48%
4528	75 Outperform	¥782.90B	10.59	9.06%	4.16%	-2.16%	-40.39%
4502	68 Neutral	¥7.00T	33.49	2.87%	4.25%	9.83%	15.49%
4523	65 Neutral	¥1.20T	20.65	6.83%	3.58%	5.63%	30.61%
Sector *	52 Neutral	$5.35B	3.83	-41.61%	2.85%	17.10%	1.22%

ONO Pharmaceutical Co Corporate Events

Ono Pharmaceutical Enhances Governance and Diversity Initiatives

Ono Pharmaceutical Co., Ltd. has announced its commitment to strengthening corporate governance by enhancing the functions of its Board of Directors and Audit & Supervisory Board. The company is also systematically reducing its cross-shareholdings to increase corporate value and is promoting diversity, equity, and inclusion within its workforce to improve employee engagement and unity. These initiatives are expected to positively impact the company’s operations and industry positioning.